Modified-release nifedipine: A review of the use of modified-release formulations in the treatment of hypertension and angina pectoris

Drugs

Volumn 66, Issue 4, 2006, Pages 497-528

  Croom, Katherine F ^a   Wellington, Keri ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Angina; Hypertension; Nifedipine; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; HYDROCHLOROTHIAZIDE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; LACIDIPINE; LERCANIDIPINE; LISINOPRIL; LOSARTAN; METOPROLOL; NEBIVOLOL; NIFEDIPINE; NISOLDIPINE; PLACEBO; TELMISARTAN; VERAPAMIL;

ABSENCE OF SIDE EFFECTS; ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; ASTHENIA; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG TOLERABILITY; FACE ERYTHEMA; FATIGUE; FLUSHING; FOOD DRUG INTERACTION; HEADACHE; HEART PALPITATION; HEART VENTRICLE HYPERTROPHY; HEAT SENSATION; HUMAN; HYPERTENSION; HYPOTENSION; LETHARGY; NAUSEA; PERIPHERAL EDEMA; REVIEW; SIDE EFFECT; ST SEGMENT DEPRESSION; STABLE ANGINA PECTORIS; SYMPATHETIC REFLEX; TACHYCARDIA; VASODILATATION;

ANGINA PECTORIS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DELAYED-ACTION PREPARATIONS; HUMANS; HYPERTENSION; NIFEDIPINE; VASODILATOR AGENTS;

EID: 33645736720     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666040-00007     Document Type: Review

References (126)

1. Bayer. The history of Bayer: Adalat [online]. Available from URL: http://www.bayer.co.jp [Accessed 2005 Sep 20]
2. Sorkin EM, Clissold SP, Brogden RN. Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs 1985; 30: 182-274
3. Bayer Yakuhin Ltd. Adalat®-CR10mg/20mg/40mg (nifedipine): prescribing information (Japan) [online]. Available from URL: http://www.jpma.or.jp [Accessed 2005 Nov 3]
4. Grundy JS, Foster RT. The nifedipine gastrointestinal therapeutic system (GITS): evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Clin Pharmacokinet 1996; 30 (1): 28-51
5. BMJ Publishing Group Ltd, Royal Pharmaceutical Society of Great Britain. Calcium channel blockers. British National Formulary 50 [online]. Available from URL: http://www.bnf.org.uk [Accessed 2006 Jan 31]
6. Breekveldt-Postma NS, Herings RMC. Persistence with antihypertensives related to formulation: the case of nifedipine. Ann Pharmacother 2005; 39 (2): 237-42
7. Whitworth JA, World Health Organization/International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-92
8. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina) [online]. Available from URL: http://www.acc.org [Accessed 2005 Nov 25]
9. Murdoch D, Brogden RN. Sustained release nifedipine formulations; an appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders. Drugs 1991; 41 (5): 737-79
10. Brogden RN, McTavish D. Nifedipine gastrointestinal therapeutic system (GITS): a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Drugs 1995; 50 (3): 495-512
11. Ting C-T, Chen J-W, Chang M-S, et al. Arterial hemodynamics in human hypertension: effects of the calcium channel antagonist nifedipine. Hypertension 1995; 25: 1326-32
12. Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation 2001; 104 (11): 1248-54
13. Schulte KL, Meyer-Sabellek W, Liederwald K, et al. Relation of regression of left ventricular hypertrophy to changes in ambulatory blood pressure after long-term therapy with perindopril versus nifedipine. Am J Cardiol 1992; 70: 468-73
14. Agabiti-Rosei E, Zulli R, Muiesan ML, et al. Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients. Blood Press 1998; 7: 160-9
15. Tsutamoto T, Tsutsui T, Maeda K, et al. Effects of long-acting calcium channel antagonists on neurohumoral factors: comparison of nifedipine coat-core with amlodipine. J Cardiovasc Pharmacol 2003; 41 Suppl. 1: 77-81
16. Hamada T, Watanabe M, Kaneda T, et al. Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine. J Hypertens 1998; 16: 111-8
17. de Champlain J, Karas M, Nguyen P, et al. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. J Hypertens 1998; 16: 1357-69
18. Kleinbloesem CH, van Brummelen P, Dahlof M, et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 1987; 41 (1): 26-30
19. Wenzel RR, Allegranza G, Binggeli C, et al. Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics. J Am Coll Cardiol 1997; 29: 1607-14
20. Fogari R, Mugellini A, Zoppi A, et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003; 16 (7): 596-9
21. Motro M, Shemesh J. Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 2001; 37 (6): 1410-3
22. Simon A, Gariepy J, Moyse D, et al. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001; 103: 2949-54
23. ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 2003; 107: 422-8
24. Schellekens S, Verheugt FWA. Hotline sessions of the 26th European Congress of Cardiology. Eur Heart J 2004; 25: 2164-6
25. Taddei S, Virdis A, Ghiadoni L, et al. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 2002; 62 (2): 265-84
26. Schiffrin EL, Deng LY. Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist. J Hypertens 1996; 14 (10): 1247-55
27. Armas-Padilla MC, Armas-Hernández MJ, Hernández- Hernández R, et al. Effect of lacidipine and nifedipine GITS on platelet function in patients with essential hypertension. J Hum Hypertens 2000 Apr; 14 Suppl. 1: 91-5
28. Koyama Y, Kodama K, Suzuki M, et al. Improvement of insulin sensitivity by a long-acting nifedipine preparation (nifedipine-CR) in patients with essential hypertension. Am J Hypertens 2002; 15: 927-31
29. Marin R, Ruilope LM, Aljama P, et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 2001; 19: 1871-6
30. Leoncini G, Martinoli C, Viazzi F, et al. Changes in renal resistive index and urinary albumin excretion in hypertensive patients under long-term treatment with lisinopril or nifedipine GITS. Nephron 2002; 90 (2): 169-73
31. Chan JC, Cockram CS, Nicholls MG, et al. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ 1992; 305: 981-5
32. Crepaldi G, Carraro A, Brocco E, et al. Hypertension and non-insulin-dependent diabetes: a comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist. Acta Diabetol 1995; 32: 203-8
33. Agardh C-D, Garcia-Puig J, Charbonnel B, et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10: 185-92
34. Baba S, The J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2001; 54: 191-201
35. Fiad TM, Cunningham SK, Hayes FJ, et al. Effects of nifedipine treatment on the renin-angiotensin-aldosterone axis. J Clin Endocrinol Metab 1997; 82 (2): 457-60
36. Minami J, Ishimitsu T, Kawano Y, et al. Effects of amlodipine and nifedipine retard on autonomic nerve activity in hypertensive patients. Clin Exp Pharm Physiol 1998; 25: 572-6
37. Leenen FH, Myers MG, Joyner CD, et al. Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: Nifedipine-GITS versus felodipine-ER versus enalapril. Can J Cardiol 2002; 18 (12): 1285-93
38. Diamond JA, Krakoff LR, Goldman A, et al. Comparison of two calcium blockers on hemodynamics, left ventricular mass, and coronary vasodilatory in advanced hypertension. Am J Hypertens 2001; 14 (3): 231-40
39. Minami J, Numabe A, Andoh N, et al. Comparison of once-daily nifedipine controlled-release with twice-daily nifedipine retard in the treatment of essential hypertension. Br J Clin Pharmacol 2004; 57 (5): 632-9
40. Schug BS, Brendel E, Wolf D, et al. Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union. Eur J Pharm Sci 2002 Apr; 15 (3): 279-85
41. Schug BS, Brendel E, Wonnemann M, et al. Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast. Eur J Clin Pharmacol 2002; 58 (2): 119-25
42. Schug BS, Brendel E, Chantraine E, et al. The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast. Br J Clin Pharmacol 2002; 53: 582-8
43. Toal CB. Formulation dependent pharmacokinetics-does the dosage form matter for nifedipine? J Cardiovasc Pharmacol 2004; 44 (1): 82-6
44. Meredith PA, Elliott HL. Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences. J Hypertens 2004; 22 (9): 1641-8
45. Data on file, Bayer Healthcare, 2006
46. Armstrong J, Challenor VF, Macklin BS, et al. The influence of two types of meal on the pharmacokinetics of a modified-release formulation of nifedipine (Adalat Retard). Eur J Clin Pharmacol 1997; 53 (2): 141-3
47. Bayer Pharmaceuticals Corporation. Adalat® CC (nifedipine) extended release tablets for oral use: prescribing information (US) [online]. Available from URL: http://www.bayer.com [Accessed 2005 Oct 3]
48. Nakamichi N, Yanagida T, Hikima Y, et al. Phase I study of nifedipine sustained-release formulation (BAY a 1040-OD tablets): single administration study. Jpn Pharmacol Ther 1995; 23 Suppl.: 7-21
49. Chung M, Reitberg DP, Gaffney M, et al. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system: a controlled-release formulation of nifedipine. Am J Med 1987; 83 Suppl. 6B: 10-4
50. Wonnemann M, Schug B, Schmucker K, et al. Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union. Int J Clin Pharmacol Ther 2006 Jan; 44 (1): 38-48
51. Bayer plc. Adalat LA 20, 30 and 60; summary of product characteristics (UK) [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2005 May 2]
52. van der Does R, Eberhardt R, Derr I, et al. Efficacy and safety of carvedilol in comparison with nifedipine sustained-release in chronic stable angina. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: S122-7
53. de Vries RJM, van den Heuvel AFM, Lok DJA, et al. Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. Netherlands Working Group on Cardiovascular Research (WCN). Int J Cardiol 1996; 57: 143-50
54. Zanolla L, Franceschini L, Rossi L, et al. Nifedipine GITS versus diltiazem in chronic stable angina: a randomised multicentre study. Br J Clin Pract 1997; Suppl. 88: 27-35
55. Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris: results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996; 27 (2): 311-6
56. Toal CB, Motro M, Baird MG, et al. Effectiveness of nifedipine GITS in combination with atenolol in chronic stable angina. Can J Cardiol 1999; 15 (10): 1103-9
57. Walker JM, Curry PVL, Bailey AE, et al. A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina. Int J Cardiol 1996; 53: 117-26
58. Lagioia R, Scrutinio D, Ricci A, et al. Comparison of a fixed combination of nifedipine slow release and atenolol (BAY-R-1999) and nifedipine slow release alone in patients with stable angina pectoris: a multicenter, randomized, double-blind, parallel-group study. BAY-R-1999 in Chronic Angina Study Group. Curr Ther Res 1995; 56 (11): 1175-84
59. Kato K, et al. Clinical evaluation of nifedipine sustained-release formulation (BAY a 1040-OD tablets) on variant form of angina pectoris: double-blind comparative study with nisoldipine (revised report) [in Japanese]. Jpn Pharmacol Ther 1997; 25: 1975-2005
60. Aschermann M, Bultas J, Karetova D, et al. Randomized double-blind comparison of isosorbide dinitrate and nifedipine in variant angina pectoris. Am J Cardiol 1990; 65 (21): 46-9
61. Kato K, et al. Investigation of clinical efficacy of BAY a 1040-OD tablets (nifedipine sustained-release formulation) on angina pectoris: multi institute, double-blind, comparative study with nifedipine Retard tablets (Adalat Rm L) (revised report) [in Japanese]. Jpn Pharmcol Ther 1997 Jul; 25: 1943-73
62. van Nueten L, Lacourcière Y, Vyssoulis G, et al. Nebivolol therapeuversus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Ther 1998; 5: 237-43
63. White WB, Black HR, Weber MA, et al. Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product. Am J Cardiol 1998; 81: 424-31
64. Schulte KL, Gotzen R, Knaup G, et al. Nifedipine in a new retard formulation vs. lisinopril: effects on 24-hour blood pressure profile in patients with essential hypertension [in German]. MMW Munch Med Wochenschr 1997; 139: 451-4
65. Weir MR, Elkins M, Liss C, et al. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996; 18 (3): 411-28
66. Zidek W, Spiecker C, Knaup G, et al. Comparison of the efficacy and safety of nifedipine coat-core versus amlodipine in the treatment of patients with mild-to-moderate essential hypertension. Clin Ther 1995; 17 (4): 686-700
67. Heagerty AM, Baksi A, Maclean D, et al. Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. BMJ 1988; 296: 468-72
68. Leonetti G. Comparative study of lacidipine and nifedipine SR in the treatment of hypertension: an Italian multicenter study. Northern Italian Study Group of Lacidipine in Hypertension. J Cardiovasc Pharmacol 1991; 17 Suppl. 4: S31-4
69. Witchitz S, Serradimigni A. Lisinopril versus slow-release nifedipine in the treatment of mild to moderate hypertension: a multicentre study. The Cooperative Study Group. J Hum Hypertens 1989; 3 Suppl. 1: 29-33
70. Rosei EA, Morelli P, Rizzoni D. Effects of nifedipine GITS 20 mg or enalapril 20 mg on blood pressure and inflammatory markers in patients with mild-moderate hypertension. Blood Press 2005; 14 Suppl. 1: 14-22
71. Hall WD, Reed JW, Flack JM, et al. Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. Arch Intern Med 1998; 158: 2029-34
72. Weir MR, Sugimoto D, Gray J, et al. Safety and efficacy of once-daily captopril plus hydrochlorothiazide versus nifedipine gastrointestinal therapeutic system in black patients with mild to moderate hypertension. Am J Ther 1996; 3: 811-7
73. Cherubini A, Fabris F, Ferrari E, et al. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003; 37 (3): 203-12
74. Clementy J, Auboiron J, Arand J-M, et al. Double-blind, randomised study of fosinopril vs nifedipine SR in the treatment of mild-to-moderate hypertension in elderly patients. Drug Invest 1991; 3 Suppl. 4: 45-53
75. Conlin PR, Elkins M, Liss C, et al. A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension. J Hum Hypertens 1998; 12: 693-9
76. Pessina AC, Boari L, De Dominicis E, et al. Efficacy, tolerability and influence on quality of life of nifedipine GITS versus amlodipine in elderly patients with mild-moderate hypertension. Blood Press 2001; 10 (3): 176-83
77. Derosa G, Cicero AFG, Bertone G, et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12 month, randomized, double-blind study. Clin Ther 2004; 26 (8): 1228-36
78. Hasebe N, Kikuchi K. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. NICE Combi Study Group. J Hypertens 2005; 23 (2): 445-53
79. Kuschnir E, Bendersky M, Resk J, et al. Effects of the combination of low-dose nifedipine GITS 20 mg and losartan 50 mg in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 2004; 43 (2): 300-5
80. MacCarthy EP, Pettis PP, Gibson L, et al. The safety and efficacy of once-daily nifedipine coat-core in combination with atenolol in hypertensive patients. The Adalat® CC Cooperative Study Group. Clin Ther 1993; 15 (6): 976-87
81. Zusman R, Christensen D, Federman E, et al. Comparison of nifedipine and propranolol used in combination with diuretics for the treatment of hypertension. Am J Med 1987; 82 Suppl. 3B: 37-41
82. Carr AA, Bottini PB, Feig P, et al. Effectiveness of once-daily monotherapy with a new nifedipine sustained release calcium antagonist. Am J Cardiol 1992; 69: 28-32E
83. Feig PU, Gibson L, MacCarthy EP, et al. The efficacy and safety of once-daily nifedipine coat-core in the treatment of mild-to-moderate hypertension. Clin Ther 1993; 15 (6): 963-75
84. Toal CB. Efficacy of a low dose nifedipine GITS (20 mg) in patients with mild to moderate hypertension. Can J Cardiol 1997; 13 (10): 921-7
85. Ishii M. Clinical evaluation on monotherapy of BAY a 1040-OD tablets (nifedipine sustained-release formulation) in patients with essential hypertension: double-blind, comparative study with nifedipine retard tablets (Adalat Rm L) (revised report) [in Japanese]. Jpn Pharmacol Ther 1997 Jul; 25: 1869-902
86. Mancia G, Omboni S, Parati G, et al. Twenty-four hour ambulatory blood pressure in the International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT). Investigators of the INSIGHT ABPM Substudy. J Hypertens 2002; 20: 545-53
87. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52
88. European Society of Hypertension - European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53. Published errata in J Hypertens 2003; 21: 2203-4 and J Hypertens 2004; 22: 435
89. Simon A, Gariepy J, Chironi G, et al. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens 2002; 20 (2): 159-69
90. Bellasi A, Raggi P. Diagnostic and prognostic value of coronary artery calcium screening. Curr Opin Cardiol 2005; 20 (5): 375-80
91. Shinoda E, Yui Y, Kodama K, et al. Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study). The Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group. Hypertension 2005; 45: 1153-8
92. Yui Y, Sumiyoshi T, Kodama K, et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004; 27: 181-91
93. Midtvedt K, Ihlen H, Hartmann A, et al. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. Transplantation 2001; 72 (1): 107-11
94. Leenen FH. Regression of cardiac hypertrophy by 1,4 dihydropyridines in hypertensive patients. J Hypertens 1998; 16 Suppl. 5: S9-15
95. Zucchelli P, Zuccala A, Borghi M, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452-8
96. de Leeuw PW, Ruilope LM, Palmer CR, et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004; 164 (22): 2459-64
97. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72
98. Poole-Wilson PA, Lubsen J, Kirwan B-A, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. The ACTION Investigators. Lancet 2004; 364 (9437): 849-57
99. Gong L, Zhang W, Zhu Y, et al. Shanghai Trial of Nifedipine in the Elderly (STONE). J Hypertens 1996; 14 (10): 1237-45
100. Mancia G, Brown M, Castaigne A, et al. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41: 431-6
101. Mancia G, Ruilope LM, Brown MJ, et al. The effect of nifedipine GITS on outcomes in patients with previous myocardial infarction: a subgroup analysis of the INSIGHT study. Br J Cardiol 2002; 9 (7): 401-5
102. Mancia G, Ruilope LM, Palmer CR, et al. Effects of nifedipine GITS and diuretics in isolated systolic hypertension: a subanalysis of the INSIGHT Study. Blood Press 2004; 13 (5): 310-5
103. Lubsen J, Wagener G, Kirwan B-A, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005; 23 (3): 641-8
104. Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial (TIBET): effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J 1996; 17 (1): 104-12
105. Yui Y, Sumiyoshi T, Kodama K, et al. Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis. Hypertens Res 2004; 27: 449-56
106. Toal CB, Mahon WA, Barnes C, et al. Nifedipine gastrointestinal therapeutic system (GITS) for hypertensive patients in a primary care setting: results of the Extended Release Adalat Canadian Trial (EXACT). The EXACT Investigators. Clin Ther 1997; 19 (5): 924-35
107. Krakoff LR, Bravo EL, Tuck ML, et al. Nifedipine gastrointestinal therapeutic system in the treatment of hypertension. Results of a multicenter trial. MATH Study Group. Am J Hypertens 1990; 3 Suppl.: 318-25
108. Bayer plc. Adalat retard: summary of product characteristics (UK) [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2005 May 2]
109. Bayer Yakuhin Ltd. Adalat®-L10mg/20mg (nifedipine) prescribing information (Japan) [online]. Available from URL: http//www.jpma.or.jp [Accessed 2005 Nov 11]
110. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92 (5): 1326-31
111. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274 (8): 620-5
112. Pahor M, Guralnik JM, Corti MC, et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43 (11): 1191-7
113. Royal Pharmaceutical Society of Great Britain. Martindale: the complete drug reference. 34th ed. London: Pharmaceutical Press, 2005
114. Grossmann E, Messerli FH. Are calcium antagonists beneficial in diabetic patients with hypertension? Am J Med 2004; 116: 44-9
115. Task Force of the European Society of Cardiology. Management of stable angina pectoris: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997; 18: 394-413
116. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet 2003; 362: 1527-35
117. Opie LH, Messerli FH. Nifedipine and mortality: grave defects in the dossier. Circulation 1995; 92: 1068-73
118. Basile J. The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens 2004; 6 (11): 621-31
119. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The ASCOT Investigators. Lancet 2005; 366 (9489): 895-906
120. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 (23): 2981-97
121. Zanchetti A, Bond MG, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. The ELSA Investigators. Circulation 2002 Nov 5; 106 (19): 2422-7
122. Nissen SE, Murat Tuzcu E, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. CAMELOT Investigators. JAMA 2004; 292 (18): 2217-26
123. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342 (3): 145-53
124. PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351 (20): 2058-68
125. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102 (13): 1503-10
126. Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. Am J Cardiol 1997; 80 (11): 1453-8